GENERIC PHARMASEC
|
|
BOM : 531592     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 07,2023 |
Price(EOD): βΉ 3.91
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Dyes & Pigments |
MCap: βΉ 108.27 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GENERIC PHARMASEC | 23.3% | 21.4% | -29.8% |
SUDARSHAN CHEMICAL INDUSTRIES | 7.2% | 18.5% | 7.7% |
KIRI INDUSTRIES | 4% | 3.7% | -34.8% |
VIDHI SPECIALTY FOOD INGREDIENTS | 5.3% | -0.3% | -9.5% |
BODAL CHEMICALS | 4.8% | -0.2% | -30.9% |
BHAGERIA INDUSTRIES | 3.6% | 1.3% | -35.7% |
SHREE PUSHKAR CHEMICALS & FERTILISERS | 8.4% | 14.7% | -24.3% |
DYNEMIC PRODUCTS | 1.5% | 8.3% | -30.4% |
ASAHI SONGWON COLORS | 17% | 15% | -23% |
FUNDAMENTAL ANALYSIS OF GENERIC PHARMASEC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GENERIC PHARMASEC
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
95.46
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1.13 Cr
[Latest Qtr - Mar2023 - Standalone Results ] 7.04
P/B Calculated based on Book Value of Rs 15.37 Cr
[Latest Year - Mar2022 - Standalone Results ] 4.24
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Mar2023 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA -70% -66% |
SHARE PRICE MOMENTUM OF GENERIC PHARMASEC
GENERIC PHARMASEC vs SENSEX
DEBT OF GENERIC PHARMASEC
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GENERIC PHARMASEC
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GENERIC PHARMASEC
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-2.94% -6.31% -13.98% 343.22% |
-16.43% 203.48% 204.64% 2515% |
QtrlyTrend |
0 | |
Latest Qtr: Mar2023 | ||
Quarterly Result Analysis → |
GENERIC PHARMASEC related INDICES
You may also like the below Video Courses
FAQ about GENERIC PHARMASEC
Is GENERIC PHARMASEC good for long term investment?
As on Jun 07,2023, the Fundamentals of GENERIC PHARMASEC look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of GENERIC PHARMASEC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GENERIC PHARMASEC UnderValued or OverValued?
As on Jun 07,2023, GENERIC PHARMASEC is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GENERIC PHARMASEC ?
As on Jun 07,2023, the Intrinsic Value of GENERIC PHARMASEC is Rs. 12.26 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -3.50
Fair Value [Median EV / Sales Model] : Rs. 13.03
Fair Value [Median Price / Sales Model] : Rs. 11.50
Estimated Median Fair Value of GENERIC PHARMASEC : Rs. 12.26
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is GENERIC PHARMASEC trading at a Premium or Discount?
As on Jun 07,2023, GENERIC PHARMASEC is trading at a Discount of -68% based on the estimates of Median Intrinsic Value!